Latest Insider Transactions at Biomarin Pharmaceutical Inc (BMRN)
This section provides a real-time view of insider transactions for Biomarin Pharmaceutical Inc (BMRN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOMARIN PHARMACEUTICAL INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOMARIN PHARMACEUTICAL INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 28
2023
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
318
+0.48%
|
$20,988
$66.88 P/Share
|
|
Apr 28
2023
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
317
+0.39%
|
$20,922
$66.88 P/Share
|
|
Apr 28
2023
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
317
+0.07%
|
$20,922
$66.88 P/Share
|
|
Apr 28
2023
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
239
+0.48%
|
$15,774
$66.88 P/Share
|
|
Apr 10
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.29%
|
$990,000
$99.56 P/Share
|
|
Apr 10
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.24%
|
$670,000
$67.81 P/Share
|
|
Apr 06
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.29%
|
$960,000
$96.13 P/Share
|
|
Apr 06
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.24%
|
$670,000
$67.81 P/Share
|
|
Apr 03
2023
|
V Bryan Lawlis Director |
SELL
Open market or private sale
|
Direct |
8,500
-22.7%
|
$824,500
$97.09 P/Share
|
|
Apr 03
2023
|
V Bryan Lawlis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+18.5%
|
$569,500
$67.81 P/Share
|
|
Mar 16
2023
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,973
-6.67%
|
$369,489
$93.41 P/Share
|
|
Mar 16
2023
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
36,000
-16.06%
|
$3,348,000
$93.41 P/Share
|
|
Mar 16
2023
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,957
-19.89%
|
$1,856,001
$93.41 P/Share
|
|
Mar 16
2023
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
88,623
-17.22%
|
$8,241,939
$93.41 P/Share
|
|
Mar 16
2023
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,510
-23.85%
|
$1,907,430
$93.41 P/Share
|
|
Mar 15
2023
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,856
-3.62%
|
$161,472
$87.74 P/Share
|
|
Mar 15
2023
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,900
+14.78%
|
-
|
|
Mar 15
2023
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,708
-4.35%
|
$235,596
$87.74 P/Share
|
|
Mar 15
2023
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,630
+13.39%
|
-
|
|
Mar 15
2023
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
4,799
-2.1%
|
$417,513
$87.74 P/Share
|
|
Mar 15
2023
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
16,840
+6.85%
|
-
|
|
Mar 15
2023
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,025
-2.93%
|
$263,175
$87.74 P/Share
|
|
Mar 15
2023
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,900
+7.93%
|
-
|
|
Mar 15
2023
|
Erin Burkhart GVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,760
+20.16%
|
-
|
|
Mar 15
2023
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9,437
-1.8%
|
$821,019
$87.74 P/Share
|
|
Mar 15
2023
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,100
+6.45%
|
-
|
|
Mar 15
2023
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,971
-4.41%
|
$345,477
$87.74 P/Share
|
|
Mar 15
2023
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,110
+10.1%
|
-
|
|
Mar 13
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
8,000
-1.61%
|
$720,000
$90.45 P/Share
|
|
Mar 13
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+1.59%
|
$536,000
$67.81 P/Share
|
|
Mar 10
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-2.98%
|
$1,380,000
$92.28 P/Share
|
|
Mar 10
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+2.9%
|
$1,005,000
$67.81 P/Share
|
|
Feb 28
2023
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,724
+12.83%
|
-
|
|
Feb 28
2023
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,890
+14.59%
|
-
|
|
Feb 28
2023
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
167,532
+11.09%
|
-
|
|
Feb 28
2023
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
68,052
+10.38%
|
-
|
|
Feb 28
2023
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,769
+15.47%
|
-
|
|
Feb 24
2023
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,474
+2.53%
|
$98,758
$67.81 P/Share
|
|
Feb 13
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
6,000
-1.84%
|
$654,000
$109.15 P/Share
|
|
Feb 13
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+1.81%
|
$402,000
$67.81 P/Share
|
|
Feb 10
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-4.47%
|
$1,650,000
$110.11 P/Share
|
|
Feb 10
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+4.28%
|
$1,005,000
$67.81 P/Share
|
|
Feb 07
2023
|
Jean Jacques Bienaime Director |
BUY
Bona fide gift
|
Indirect |
200
+50.0%
|
-
|
|
Feb 07
2023
|
Jean Jacques Bienaime Director |
SELL
Bona fide gift
|
Indirect |
200
-0.08%
|
-
|
|
Jan 25
2023
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
49,000
-29.49%
|
$5,635,000
$115.9 P/Share
|
|
Jan 25
2023
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,000
+35.23%
|
$3,283,000
$67.81 P/Share
|
|
Jan 17
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-3.03%
|
$1,110,000
$111.55 P/Share
|
|
Jan 17
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.94%
|
$670,000
$67.81 P/Share
|
|
Jan 13
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-3.03%
|
$1,120,000
$112.25 P/Share
|
|
Jan 13
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.94%
|
$670,000
$67.81 P/Share
|